Hematology Frontier

The 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9, 2025. As the world’s largest and most influential hematology conference,…

Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative option for patients with myelodysplastic syndromes (MDS). However, clinical decision-making in the transplant setting remains challenging. Two critical and unresolved issues…

The 2025 Annual Meeting of the American Society of Hematology (ASH) was held in Orlando from December 6 to 9. As one of the world’s premier events in hematology, the…

CAR-T cell therapy has achieved transformative success in lymphoid malignancies, yet its application in acute myeloid leukemia (AML) remains highly challenging. Against this backdrop, a sequential strategy integrating CD7-targeted CAR-T…

At a recent Annual Meeting of the American Society of Hematology (ASH), a prospective study conducted by Prof. Yi Luo’s team at The First Affiliated Hospital, Zhejiang University School of…

December 6–9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the world’s largest and most influential hematology conference, ASH annually…

At the 67th Annual Meeting of the American Society of Hematology (ASH), Professor Lu Peihua and Professor Zhang Xian from Lu Daopei Hospital presented a large-scale clinical study of a…

Immune thrombocytopenia (ITP) is an immune-mediated thrombocytopenic disorder that can lead to severe bleeding and markedly impair quality of life. At the 67th Annual Meeting of the American Society of…

On December 6 (local time), a highly anticipated special session on the ASH Clinical Practice Guidelines on Myelofibrosis was successfully held during the American Society of Hematology (ASH) Annual Meeting.…

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the world’s largest and most influential international…